董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| James M. Hindman | 男 | Director | 65 | 20.87万美元 | 未持股 | 2025-11-13 |
| Beverly A. Huss | 女 | Director | 65 | 19.87万美元 | 未持股 | 2025-11-13 |
| Anne B. Le Grand | 女 | Director | 74 | 22.74万美元 | 未持股 | 2025-11-13 |
| Byron C. Scott | 男 | Director | 62 | 19.12万美元 | 未持股 | 2025-11-13 |
| Mika Nishimura | 女 | Director | 62 | 18.87万美元 | 未持股 | 2025-11-13 |
| Chan W. Galbato | 男 | Director | 62 | 未披露 | 未持股 | 2025-11-13 |
| Stephen La Neve | 男 | Director,President and Chief Executive Officer | 66 | 未披露 | 未持股 | 2025-11-13 |
| Steven F. Mayer | 男 | Director | 65 | 6.61万美元 | 未持股 | 2025-11-13 |
| Joseph E. Whitters | 男 | Chairman of the Board | 67 | 28.24万美元 | 未持股 | 2025-11-13 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jesse Chew | 男 | Senior Vice President, Chief Legal Officer and Corporate Secretary | 44 | 136.84万美元 | 未持股 | 2025-11-13 |
| Ali Pervaiz | 男 | Senior Vice President and Chief Financial Officer | 45 | 109.79万美元 | 未持股 | 2025-11-13 |
| Sandeep Chalke | 男 | Senior Vice President and Chief Commercial Officer | 59 | 119.93万美元 | 未持股 | 2025-11-13 |
| Leonel Peralta | 男 | Senior Vice President and Chief Operations Officer | 55 | 未披露 | 未持股 | 2025-11-13 |
| Stephen La Neve | 男 | Director,President and Chief Executive Officer | 66 | 未披露 | 未持股 | 2025-11-13 |
董事简历
中英对照 | 中文 | 英文- James M. Hindman
-
James M. Hindman，自2019年9月起担任Accuray Incorporated董事会成员。Hindman先生曾于1984年至2015年3月在眼力健制药公司（“Allergan”）担任多个职位，该公司是一家多专业的医疗保健公司，于2015年被Actavis PLC收购，在该公司担任的职务越来越重要，包括最近担任的财务和业务发展执行副总裁，以及2014年8月至2015年3月担任首席财务官。Hindman先生于2002年3月至2014年8月在Allergan担任财务、风险和投资者关系高级副总裁。从1984年至2002年，Hindman先生在Allergan担任过多个其他财务职位，包括高级副总裁、财务和财务总监；财务副总裁；财务规划和分析副总裁；助理公司财务总监。Hindman先生目前担任私营医疗器械公司Aatru Medical，LLC的董事会成员。在过去五年中，Hindman先生于2016年6月至2021年6月担任上市生物技术公司Millendo Therapeutics, Inc.的董事会成员，于2018年8月至2019年12月担任公共临床阶段医学皮肤病学和美学公司Sienna Biopharmaceuticals, Inc.的董事会成员，于2020年6月至2023年3月担任私营生物制药公司Urovant Sciences，Inc.的董事会成员，并于2021年7月至2024年担任专门开发内分泌和代谢疾病治疗性多肽的私营公司Amolyt Pharma SAS的董事会成员。还自2015年7月起为上市生物技术公司Cidara Therapeutics, Inc.提供财务咨询服务，并于2017年12月至2018年12月为民营生物技术公司RANI Therapeutics Holdings，Inc.提供财务咨询服务。Hindman先生拥有Loyola Marymount大学会计学学士学位和Pepperdine大学工商管理硕士学位。他是加利福尼亚州的注册会计师（非在职）。
James M. Hindman has served as a member of Board since September 2019. Mr. Hindman served in vario positions at Allergan, Inc. ("Allergan"), a multi specialty healthcare company that was acquired by Actavis PLC in 2015, from 1984 to March 2015, where he held positions of increasing responsibility, including most recently as the Executive Vice President, Finance and Biness Development, and Chief Financial Officer from Augt 2014 to March 2015. Mr. Hindman served as Senior Vice President of Treasury, Risk and Investor Relations at Allergan from March 2002 to Augt 2014, and, from 1984 to 2002, Mr. Hindman served a variety of other finance positions at Allergan, including Senior Vice President, Finance and Controller; Vice President, Finance; Vice President, Financial Planning and Analysis; and Assistant Corporate Controller. Mr. Hindman currently serves on the board of directors of Aatru Medical, LLC, a private medical device company. In the past five years, Mr. Hindman served on the board of directors of Millendo Therapeutics, Inc., a public biotechnology company, from June 2016 to June 2021; Sienna Biopharmaceuticals, Inc., a public clinical stage medical dermatology and aesthetics company, from Augt 2018 to December 2019; Urovant Sciences, Inc., a private biopharmaceutical company, from June 2020 to March 2023; and Amolyt Pharma SAS, a private company specializing in developing therapeutic peptides for endocrine and metabolic disease, from July 2021 to July 2024. He has also provided financial consulting services to Cidara Therapeutics, Inc., a public biotechnology company, since July 2015, and to RANI Therapeutics Holdings, Inc., a private biotechnology company, from December 2017 to December 2018. Mr. Hindman holds a B.S. in Accounting from Loyola Marymount University and a M.B.A. from Pepperdine University. He is a certified public accountant in the state of California (inactive). - James M. Hindman，自2019年9月起担任Accuray Incorporated董事会成员。Hindman先生曾于1984年至2015年3月在眼力健制药公司（“Allergan”）担任多个职位，该公司是一家多专业的医疗保健公司，于2015年被Actavis PLC收购，在该公司担任的职务越来越重要，包括最近担任的财务和业务发展执行副总裁，以及2014年8月至2015年3月担任首席财务官。Hindman先生于2002年3月至2014年8月在Allergan担任财务、风险和投资者关系高级副总裁。从1984年至2002年，Hindman先生在Allergan担任过多个其他财务职位，包括高级副总裁、财务和财务总监；财务副总裁；财务规划和分析副总裁；助理公司财务总监。Hindman先生目前担任私营医疗器械公司Aatru Medical，LLC的董事会成员。在过去五年中，Hindman先生于2016年6月至2021年6月担任上市生物技术公司Millendo Therapeutics, Inc.的董事会成员，于2018年8月至2019年12月担任公共临床阶段医学皮肤病学和美学公司Sienna Biopharmaceuticals, Inc.的董事会成员，于2020年6月至2023年3月担任私营生物制药公司Urovant Sciences，Inc.的董事会成员，并于2021年7月至2024年担任专门开发内分泌和代谢疾病治疗性多肽的私营公司Amolyt Pharma SAS的董事会成员。还自2015年7月起为上市生物技术公司Cidara Therapeutics, Inc.提供财务咨询服务，并于2017年12月至2018年12月为民营生物技术公司RANI Therapeutics Holdings，Inc.提供财务咨询服务。Hindman先生拥有Loyola Marymount大学会计学学士学位和Pepperdine大学工商管理硕士学位。他是加利福尼亚州的注册会计师（非在职）。
- James M. Hindman has served as a member of Board since September 2019. Mr. Hindman served in vario positions at Allergan, Inc. ("Allergan"), a multi specialty healthcare company that was acquired by Actavis PLC in 2015, from 1984 to March 2015, where he held positions of increasing responsibility, including most recently as the Executive Vice President, Finance and Biness Development, and Chief Financial Officer from Augt 2014 to March 2015. Mr. Hindman served as Senior Vice President of Treasury, Risk and Investor Relations at Allergan from March 2002 to Augt 2014, and, from 1984 to 2002, Mr. Hindman served a variety of other finance positions at Allergan, including Senior Vice President, Finance and Controller; Vice President, Finance; Vice President, Financial Planning and Analysis; and Assistant Corporate Controller. Mr. Hindman currently serves on the board of directors of Aatru Medical, LLC, a private medical device company. In the past five years, Mr. Hindman served on the board of directors of Millendo Therapeutics, Inc., a public biotechnology company, from June 2016 to June 2021; Sienna Biopharmaceuticals, Inc., a public clinical stage medical dermatology and aesthetics company, from Augt 2018 to December 2019; Urovant Sciences, Inc., a private biopharmaceutical company, from June 2020 to March 2023; and Amolyt Pharma SAS, a private company specializing in developing therapeutic peptides for endocrine and metabolic disease, from July 2021 to July 2024. He has also provided financial consulting services to Cidara Therapeutics, Inc., a public biotechnology company, since July 2015, and to RANI Therapeutics Holdings, Inc., a private biotechnology company, from December 2017 to December 2018. Mr. Hindman holds a B.S. in Accounting from Loyola Marymount University and a M.B.A. from Pepperdine University. He is a certified public accountant in the state of California (inactive).
- Beverly A. Huss
-
BeverlyA.Huss自2018年1月起担任董事会成员。2013年9月起，她担任Qool Therapeutics，Inc.（前身为Thermocure，Inc.）的总裁兼首席执行官，该公司是一家开发阶段公司，专注于为心脏病发作、中风、颅脑创伤和其他医疗状况下的组织保护创造一种新型非侵入性设备。加入Qool之前，Huss从2006年1月到2013年3月担任Vibrynt，Inc.（一家早期医疗设备公司）总裁和首席执行官。此前，她曾担任Guidant Corporation的多种高级领导职务（从1986年到2005年），包括最近担任血管内解决方案总裁，以及血管干预全球营销Vice President。Huss女士的职业生涯始于1982年担任中国中冶工程师。Huss女士目前任职于Qool and Madorra的董事会，该公司是一家私人控股的医疗器械公司，开发改善更年期后生活质量的解决方案。她之前的上市公司董事会经验包括Artes Medical，Wright Medical Group和Dade Behring Holdings，Inc.。Huss女士拥有Pepperdine大学技术管理硕士学位和Illinois大学中国中冶工程学士学位。
Beverly A. Huss has served as a member of Board since January 2018. From January 2021 to July 2022, Ms. Hs served as the Chief Executive Officer of Pagonia Medical, Inc. ("Pagonia"), a private company foced on creating a novel non invasive device for the preservation of tissue following a heart attack, stroke, traumatic brain injury and other medical conditions. From September 2013 until December 2020, she served as President and Chief Executive Officer of Qool Therapeutics, Inc. ("Qool"), formerly Thermocure, Inc., a private company foced on temperature management therapies. Prior to joining Qool, Ms. Hs was President and Chief Executive Officer at start up medical device company Vibrynt, Inc., and held multiple senior level leadership positions at Guidant Corporation, a public company that designs and manufactures cardiovascular products, including, most recently President, Endovascular Solutions, Vice President, Global Marketing, Vascular Intervention and Vice President of the Stent Biness Unit. Ms. Hs has served on the board of directors of Vicario Surgical Inc., a public medical robotics company, since October 2022; Infystems Holdings, Inc, a national healthcare service provider since May 2024; Iridex Corporation, a public medical device company, since March 2022; Ancora Heart, Inc., a privately held medical device company developing heart failure treatments, since June 2021; and Clari Mobile Health, an inventor of high definition handheld ultrasound systems, since October 2024. Her prior private company board experience includes Pagonia; Coala Life, Inc.; Artes Medical, Inc.; Madorra Inc.; Wright Medical Group, Inc.; and Dade Behring Holdings, Inc. Ms. Hs holds a M.S. in technology management from Pepperdine University and a B.S. in metallurgical engineering from the University of Illinois. Ms. Hs has National Association of Corporate Directors ("NACD") certification. - BeverlyA.Huss自2018年1月起担任董事会成员。2013年9月起，她担任Qool Therapeutics，Inc.（前身为Thermocure，Inc.）的总裁兼首席执行官，该公司是一家开发阶段公司，专注于为心脏病发作、中风、颅脑创伤和其他医疗状况下的组织保护创造一种新型非侵入性设备。加入Qool之前，Huss从2006年1月到2013年3月担任Vibrynt，Inc.（一家早期医疗设备公司）总裁和首席执行官。此前，她曾担任Guidant Corporation的多种高级领导职务（从1986年到2005年），包括最近担任血管内解决方案总裁，以及血管干预全球营销Vice President。Huss女士的职业生涯始于1982年担任中国中冶工程师。Huss女士目前任职于Qool and Madorra的董事会，该公司是一家私人控股的医疗器械公司，开发改善更年期后生活质量的解决方案。她之前的上市公司董事会经验包括Artes Medical，Wright Medical Group和Dade Behring Holdings，Inc.。Huss女士拥有Pepperdine大学技术管理硕士学位和Illinois大学中国中冶工程学士学位。
- Beverly A. Huss has served as a member of Board since January 2018. From January 2021 to July 2022, Ms. Hs served as the Chief Executive Officer of Pagonia Medical, Inc. ("Pagonia"), a private company foced on creating a novel non invasive device for the preservation of tissue following a heart attack, stroke, traumatic brain injury and other medical conditions. From September 2013 until December 2020, she served as President and Chief Executive Officer of Qool Therapeutics, Inc. ("Qool"), formerly Thermocure, Inc., a private company foced on temperature management therapies. Prior to joining Qool, Ms. Hs was President and Chief Executive Officer at start up medical device company Vibrynt, Inc., and held multiple senior level leadership positions at Guidant Corporation, a public company that designs and manufactures cardiovascular products, including, most recently President, Endovascular Solutions, Vice President, Global Marketing, Vascular Intervention and Vice President of the Stent Biness Unit. Ms. Hs has served on the board of directors of Vicario Surgical Inc., a public medical robotics company, since October 2022; Infystems Holdings, Inc, a national healthcare service provider since May 2024; Iridex Corporation, a public medical device company, since March 2022; Ancora Heart, Inc., a privately held medical device company developing heart failure treatments, since June 2021; and Clari Mobile Health, an inventor of high definition handheld ultrasound systems, since October 2024. Her prior private company board experience includes Pagonia; Coala Life, Inc.; Artes Medical, Inc.; Madorra Inc.; Wright Medical Group, Inc.; and Dade Behring Holdings, Inc. Ms. Hs holds a M.S. in technology management from Pepperdine University and a B.S. in metallurgical engineering from the University of Illinois. Ms. Hs has National Association of Corporate Directors ("NACD") certification.
- Anne B. Le Grand
-
Anne B.Le Grand自2020年7月起担任董事会成员。Le Grand女士自2019年7月起担任IBM Watson Health的Vice President兼成像，生命科学，肿瘤学和基因组学总经理，这是一家机器智能公司，是信息技术公司国际商业机器公司（IBM“；IBM”；）的一个部门。Le Grand女士还于2016年4月至2019年7月担任IBM Watson Health的影像副总裁兼总经理。在IBM Watson Health任职之前，Le Grand女士于2015年1月至2016年4月担任梦百合高级副总裁兼Therapeutics总经理，并于2014年1月至2015年1月担任健康技术公司Philips梦百合业务转型高级副总裁。Le Grand女士此前曾在GE梦百合和Eastman Kodak Company担任多个高级领导职位，并在3M公司医学影像部门开始了她的职业生涯。Le Grand女士拥有夏洛特皇后大学（Queens University of Charlotte）化学学士学位。
Anne B. Le Grand has served as a member of Board since July 2020. Ms. Le Grand served as a consultant to IBM Watson Health, a machine intelligence company that is a division of IBM, a publicly traded information technology company, from January 2021 to January 2023. Prior to that, Ms. Le Grand also served as Vice President and General Manager of Imaging, Life Sciences, Oncology and Genomics at IBM Watson Health from July 2019 to December 2020 and VP and General Manager of Imaging at IBM Watson Health from April 2016 to July 2019. Prior to her roles at IBM Watson Health, Ms. Le Grand served as Senior Vice President of Healthcare and General Manager of Therapeutics from January 2015 to April 2016 and Senior Vice President of Healthcare Biness Transformation from January 2014 to January 2015 at Koninkliike Philips N.V., a health technology company. Ms. Le Grand previoly served in vario senior leadership positions at GE HealthCare Technologies Inc. and Eastman Kodak Company and began her career at 3M Company in the Medical Imaging Division. Ms. Le Grand has served as a member of the board of directors of Medimaps Group, SA, a private medical analytics software company, since May 2022. Ms. Le Grand holds a B.S. in Chemistry from Queens University of Charlotte. - Anne B.Le Grand自2020年7月起担任董事会成员。Le Grand女士自2019年7月起担任IBM Watson Health的Vice President兼成像，生命科学，肿瘤学和基因组学总经理，这是一家机器智能公司，是信息技术公司国际商业机器公司（IBM“；IBM”；）的一个部门。Le Grand女士还于2016年4月至2019年7月担任IBM Watson Health的影像副总裁兼总经理。在IBM Watson Health任职之前，Le Grand女士于2015年1月至2016年4月担任梦百合高级副总裁兼Therapeutics总经理，并于2014年1月至2015年1月担任健康技术公司Philips梦百合业务转型高级副总裁。Le Grand女士此前曾在GE梦百合和Eastman Kodak Company担任多个高级领导职位，并在3M公司医学影像部门开始了她的职业生涯。Le Grand女士拥有夏洛特皇后大学（Queens University of Charlotte）化学学士学位。
- Anne B. Le Grand has served as a member of Board since July 2020. Ms. Le Grand served as a consultant to IBM Watson Health, a machine intelligence company that is a division of IBM, a publicly traded information technology company, from January 2021 to January 2023. Prior to that, Ms. Le Grand also served as Vice President and General Manager of Imaging, Life Sciences, Oncology and Genomics at IBM Watson Health from July 2019 to December 2020 and VP and General Manager of Imaging at IBM Watson Health from April 2016 to July 2019. Prior to her roles at IBM Watson Health, Ms. Le Grand served as Senior Vice President of Healthcare and General Manager of Therapeutics from January 2015 to April 2016 and Senior Vice President of Healthcare Biness Transformation from January 2014 to January 2015 at Koninkliike Philips N.V., a health technology company. Ms. Le Grand previoly served in vario senior leadership positions at GE HealthCare Technologies Inc. and Eastman Kodak Company and began her career at 3M Company in the Medical Imaging Division. Ms. Le Grand has served as a member of the board of directors of Medimaps Group, SA, a private medical analytics software company, since May 2022. Ms. Le Grand holds a B.S. in Chemistry from Queens University of Charlotte.
- Byron C. Scott
-
Byron C.Scott自2021年2月起担任我们的董事会成员。Scott博士自2016年以来一直担任马萨诸塞州阿默斯特大学艾森伯格管理学院的兼职教师，自2019年12月以来一直担任托马斯·杰斐逊大学杰斐逊人口健康学院的兼职教师，在那里他教授医疗保健质量，患者安全和性能改进。Scott博士于2017年3月至2020年6月担任IBM Watson Health的副首席健康官，在那里他担任顾问，帮助医疗保健组织调整战略并提高绩效，并支持销售，营销和思想领导力。Scott博士曾在Truven Health Analytics任职，该公司于2014年1月至2017年2月被IBM收购，最近于2015年至2017年担任副首席医疗官。从1995年到2013年，他曾任职Emcare公司（医院的医生实践管理公司，是Envision医疗保健的一部分），在那里他担任越来越重要的职务，包括最近担任西部部门的执行副总裁（从2011年到2013年）。Scott博士获得了急诊医学委员会认证，此前从事医学工作超过25年。他目前担任Direct Relief（一个非营利性人道主义组织）的董事会成员，以及the Rady Children’；s Hospital-San Diego的董事会受托人。Scott博士拥有加州大学洛杉矶分校的心理生物学学士学位，加州大学圣地亚哥分校的M.D.和马萨诸塞大学安默斯特分校伊森伯格管理学院的M.B.A.。他是美国企业董事协会认证的董事，并持有卡内基梅隆大学和NACD颁发的CERT网络安全监督证书。
Byron C. Scott has served as a member of Board since February 2021. Dr. Scott has served as the interim Chief Operating Officer at Direct Relief, a nonprofit humanitarian aid organization, since January 2024. He was interim Chief Executive Officer at Direct Relief from January 2025 to April 2025. Dr. Scott previoly served on the Board of Directors at Direct Relief from June 2016 to January 2024. Dr. Scott has served as Adjunct Faculty at the University of Massachetts, Amherst, Isenberg School of Management since 2016 and Adjunct Faculty at Jefferson University, College of Population Health since December 2019 where he teaches healthcare quality, patient safety, and performance improvement. Dr. Scott served as Adjunct, Associate Professor at New York University Stern School of Biness from January 2023 to December 2023. Dr. Scott served as Deputy Chief Health Officer at IBM Watson Health from March 2017 to June 2020, where he served as a consultant helping healthcare organizations align strategies and improve performance, along with supporting sales, marketing, and thought leadership. Dr. Scott served at Truven Health Analytics., an IBM Watson Health company that provides healthcare analytics, from January 2014 to February 2017, most recently as Associate Chief Medical Officer from 2015 to 2017, prior to its acquisition by IBM in 2016. Dr. Scott previoly served at EmCare Holdings Inc., a private hospital based physician practice management company that was part of Envision Healthcare, from 1995 to 2013, where he held positions of increasing responsibility, including most recently as Executive Vice President of the st Division from 2011 to 2013. Dr. Scott is board certified in emergency medicine and previoly practiced medicine for over 25 years. He currently serves as a member of the Board of Directors of Providence Health Plan, a privately held health insurance provider. In addition, Dr. Scott also currently serves as Board Trtee, and member of the Quality, Patient Safety, and Medical Affairs Committee of the Board of Directors at Rady Children's Hospital San Diego and Board Trtee for Rady Children's Health. Dr. Scott holds a B.S. in Psychobiology from the University of California, Los Angeles, a M.D. from the University of California, San Diego, and a M.B.A. from the University of Massachetts, Amherst, Isenberg School of Management. He is Directorship Certified by the NACD and a CERT Cybersecurity Oversight Certification issued by Carnegie Mellon University and NACD. - Byron C.Scott自2021年2月起担任我们的董事会成员。Scott博士自2016年以来一直担任马萨诸塞州阿默斯特大学艾森伯格管理学院的兼职教师，自2019年12月以来一直担任托马斯·杰斐逊大学杰斐逊人口健康学院的兼职教师，在那里他教授医疗保健质量，患者安全和性能改进。Scott博士于2017年3月至2020年6月担任IBM Watson Health的副首席健康官，在那里他担任顾问，帮助医疗保健组织调整战略并提高绩效，并支持销售，营销和思想领导力。Scott博士曾在Truven Health Analytics任职，该公司于2014年1月至2017年2月被IBM收购，最近于2015年至2017年担任副首席医疗官。从1995年到2013年，他曾任职Emcare公司（医院的医生实践管理公司，是Envision医疗保健的一部分），在那里他担任越来越重要的职务，包括最近担任西部部门的执行副总裁（从2011年到2013年）。Scott博士获得了急诊医学委员会认证，此前从事医学工作超过25年。他目前担任Direct Relief（一个非营利性人道主义组织）的董事会成员，以及the Rady Children’；s Hospital-San Diego的董事会受托人。Scott博士拥有加州大学洛杉矶分校的心理生物学学士学位，加州大学圣地亚哥分校的M.D.和马萨诸塞大学安默斯特分校伊森伯格管理学院的M.B.A.。他是美国企业董事协会认证的董事，并持有卡内基梅隆大学和NACD颁发的CERT网络安全监督证书。
- Byron C. Scott has served as a member of Board since February 2021. Dr. Scott has served as the interim Chief Operating Officer at Direct Relief, a nonprofit humanitarian aid organization, since January 2024. He was interim Chief Executive Officer at Direct Relief from January 2025 to April 2025. Dr. Scott previoly served on the Board of Directors at Direct Relief from June 2016 to January 2024. Dr. Scott has served as Adjunct Faculty at the University of Massachetts, Amherst, Isenberg School of Management since 2016 and Adjunct Faculty at Jefferson University, College of Population Health since December 2019 where he teaches healthcare quality, patient safety, and performance improvement. Dr. Scott served as Adjunct, Associate Professor at New York University Stern School of Biness from January 2023 to December 2023. Dr. Scott served as Deputy Chief Health Officer at IBM Watson Health from March 2017 to June 2020, where he served as a consultant helping healthcare organizations align strategies and improve performance, along with supporting sales, marketing, and thought leadership. Dr. Scott served at Truven Health Analytics., an IBM Watson Health company that provides healthcare analytics, from January 2014 to February 2017, most recently as Associate Chief Medical Officer from 2015 to 2017, prior to its acquisition by IBM in 2016. Dr. Scott previoly served at EmCare Holdings Inc., a private hospital based physician practice management company that was part of Envision Healthcare, from 1995 to 2013, where he held positions of increasing responsibility, including most recently as Executive Vice President of the st Division from 2011 to 2013. Dr. Scott is board certified in emergency medicine and previoly practiced medicine for over 25 years. He currently serves as a member of the Board of Directors of Providence Health Plan, a privately held health insurance provider. In addition, Dr. Scott also currently serves as Board Trtee, and member of the Quality, Patient Safety, and Medical Affairs Committee of the Board of Directors at Rady Children's Hospital San Diego and Board Trtee for Rady Children's Health. Dr. Scott holds a B.S. in Psychobiology from the University of California, Los Angeles, a M.D. from the University of California, San Diego, and a M.B.A. from the University of Massachetts, Amherst, Isenberg School of Management. He is Directorship Certified by the NACD and a CERT Cybersecurity Oversight Certification issued by Carnegie Mellon University and NACD.
- Mika Nishimura
-
Mika Nishimura自2021年8月起担任我们的董事会成员。自2011年以来，Nishimura女士一直担任Gilde医疗保健Partners（一家专注于生命科学的风险基金）的运营合伙人。她还担任SI-BONE，Inc.的董事会成员，这是一家公共医疗设备公司，致力于解决骨盆解剖的肌肉骨骼疾病。从2015年到2020年，Nishimura女士担任Nvision Medical Corporation的商业化副总裁，这是一家被Boston Scientific收购的早期临床阶段医疗设备公司。此前，她曾担任Auxogyn Incorporated（医疗技术公司，被Progyny，Inc.收购）的商业开发副总裁。职业生涯早期，她曾担任EV3Incorporated公司的副总裁，负责国际销售运营和营销，在那里她曾负责新兴市场的损益。Nishimura女士拥有耶鲁大学经济学学士学位和哈佛大学工商管理研究生院工商管理硕士学位。
Mika Nishimura has served as a member of Board since Augt 2021. Since 2011, Ms. Nishimura has served as an Operational Partner with Gilde Healthcare Partners, a life science foced venture fund. From 2015 to 2020, Ms. Nishimura served as Vice President of Commercialization at nVision Medical Corporation, an early clinical stage medical device company acquired by Boston Scientific. Previoly, she served as Vice President, Commercial Development at Auxogyn, Inc., a private medical technology company, acquired by Progyny, Inc. Earlier in her career, Ms. Nishimura served as Vice President of International Sales Operations and Marketing at ev3 Inc., a provider for specialists treating a wide range of vascular diseases and disorders, where she held P&L responsibilities for the emerging markets. She has also served as a board member of SI BONE, Inc., a public medical device company dedicated to solving mculoskeletal disorders of the sacropelvic anatomy, since March 2021; a board member of HOYA Corp, a publicly listed Japanese company manufacturing optical products, since June 2022; a board advisor to Tristel, plc, a UK public medical technology company, since January 2021; and a board member of NEC Corporation, a publicly listed Japanese company leveraging its IT, AI, and communication technologies since June 2025. Ms. Nishimura holds an MBA from Harvard Graduate School of Biness Administration and a B.A. in Economics from Yale University. - Mika Nishimura自2021年8月起担任我们的董事会成员。自2011年以来，Nishimura女士一直担任Gilde医疗保健Partners（一家专注于生命科学的风险基金）的运营合伙人。她还担任SI-BONE，Inc.的董事会成员，这是一家公共医疗设备公司，致力于解决骨盆解剖的肌肉骨骼疾病。从2015年到2020年，Nishimura女士担任Nvision Medical Corporation的商业化副总裁，这是一家被Boston Scientific收购的早期临床阶段医疗设备公司。此前，她曾担任Auxogyn Incorporated（医疗技术公司，被Progyny，Inc.收购）的商业开发副总裁。职业生涯早期，她曾担任EV3Incorporated公司的副总裁，负责国际销售运营和营销，在那里她曾负责新兴市场的损益。Nishimura女士拥有耶鲁大学经济学学士学位和哈佛大学工商管理研究生院工商管理硕士学位。
- Mika Nishimura has served as a member of Board since Augt 2021. Since 2011, Ms. Nishimura has served as an Operational Partner with Gilde Healthcare Partners, a life science foced venture fund. From 2015 to 2020, Ms. Nishimura served as Vice President of Commercialization at nVision Medical Corporation, an early clinical stage medical device company acquired by Boston Scientific. Previoly, she served as Vice President, Commercial Development at Auxogyn, Inc., a private medical technology company, acquired by Progyny, Inc. Earlier in her career, Ms. Nishimura served as Vice President of International Sales Operations and Marketing at ev3 Inc., a provider for specialists treating a wide range of vascular diseases and disorders, where she held P&L responsibilities for the emerging markets. She has also served as a board member of SI BONE, Inc., a public medical device company dedicated to solving mculoskeletal disorders of the sacropelvic anatomy, since March 2021; a board member of HOYA Corp, a publicly listed Japanese company manufacturing optical products, since June 2022; a board advisor to Tristel, plc, a UK public medical technology company, since January 2021; and a board member of NEC Corporation, a publicly listed Japanese company leveraging its IT, AI, and communication technologies since June 2025. Ms. Nishimura holds an MBA from Harvard Graduate School of Biness Administration and a B.A. in Economics from Yale University.
- Chan W. Galbato
-
Chan W. Galbato自2025年3月起担任私人投资公司Barington Capital Group，LP的高级顾问，自2025年8月起担任咨询公司Alvarez Marsal Holdings，LLC的高级顾问。Previoly，他曾于2012年至2024年担任私人投资公司Cerber Capital Management的全球运营平台Cerber Operations and Advisory Company，LLC的首席执行官。在2009年加入Cerber之前，Galbato先生曾担任全球科技公司Invesys plc的Controls Group总裁兼首席执行官。在此之前，他曾担任家得宝的服务和公司商业分销部门总裁；Armstrong World Indtries的一个部门Armstrong Floor Products的总裁兼首席执行官；合资初创公司Choice Parts的首席执行官；以及GE Capital旗下公司Coregis Insurance Company的总裁兼首席执行官。他在通用电气公司工作了十几年，在其多个工业部门（包括运输系统、飞机发动机、医疗系统和设备）担任过多个运营和财务领导职务。Galbato先生自2025年5月以来，曾在多家公司的董事会、审计委员会、提名和治理委员会、薪酬委员会、财务委员会和技术委员会任职，这些公司包括上市的工程和制造公司The Eastern Company，NFi Group Inc.，一家上市的跨国b制造商，于2025年1月至2025年4月；丨艾伯森公司，Inc.，一家上市的食品和药品零售公司，于2021年4月至2024年10月；Blue Bird Corporation，一家上市的学校BE和特种车辆制造商，于2015年2月至2023年4月；Autob，Inc.，上市的汽车工业数字营销公司，2019年1月至2022年5月；以及上市的化妆品和美容公司雅芳产品有限公司,2016年3月至2020年1月。Galbato先生拥有纽约州立大学经济学学士学位和芝加哥大学工商管理硕士学位。
Chan W. Galbato has been Senior Advisor to Barington Capital Group, LP, a private investment firm, since March 2025, and Alvarez Marsal Holdings, LLC, a consulting firm, since Augt 2025. Previoly, he was the Chief Executive Officer of Cerber Operations and Advisory Company, LLC, the global operating platform of Cerber Capital Management, a private investment company, from 2012 to 2024. Prior to joining Cerber in 2009, Mr. Galbato served as President and Chief Executive Officer of the Controls Group of Invesys plc, a global technology company. Prior to that, he served as President of Services and of the commercial distribution arm of companies for The Home Depot; President and Chief Executive Officer of Armstrong Floor Products, a division of Armstrong World Indtries; Chief Executive Officer of Choice Parts, a joint venture start up; and President and Chief Executive Officer of Coregis Insurance Company, a GE Capital company. He spent fteen years with General Electric Company, holding several operating and finance leadership positions within their vario indtrial divisions (including Transportation Systems, Aircraft Engines, Medical Systems and Appliances). Mr. Galbato has served on the boards of directors, audit committees, nominating and governance committees, compensation committees, finance committees and technology committees of vario companies, including The Eastern Company, a publicly traded engineering and manufacturing company, since May 2025, NFI Group Inc., a publicly traded multinational b manufacturer, from January 2025 to April 2025; Albertsons Companies, Inc., a publicly traded food and drug retail company, from April 2021 to October 2024; Blue Bird Corporation, a publicly traded manufacturer of school bes and specialty vehicles, from February 2015 to April 2023; Autob, Inc., a publicly traded digital marketing company for the automotive indtry, from January 2019 to May 2022; and Avon Products, Inc., a publicly traded cosmetics and beauty company, from March 2016 to January 2020. Mr. Galbato holds a B.A. in Economics from the State University of New York and an M.B.A. from the University of Chicago. - Chan W. Galbato自2025年3月起担任私人投资公司Barington Capital Group，LP的高级顾问，自2025年8月起担任咨询公司Alvarez Marsal Holdings，LLC的高级顾问。Previoly，他曾于2012年至2024年担任私人投资公司Cerber Capital Management的全球运营平台Cerber Operations and Advisory Company，LLC的首席执行官。在2009年加入Cerber之前，Galbato先生曾担任全球科技公司Invesys plc的Controls Group总裁兼首席执行官。在此之前，他曾担任家得宝的服务和公司商业分销部门总裁；Armstrong World Indtries的一个部门Armstrong Floor Products的总裁兼首席执行官；合资初创公司Choice Parts的首席执行官；以及GE Capital旗下公司Coregis Insurance Company的总裁兼首席执行官。他在通用电气公司工作了十几年，在其多个工业部门（包括运输系统、飞机发动机、医疗系统和设备）担任过多个运营和财务领导职务。Galbato先生自2025年5月以来，曾在多家公司的董事会、审计委员会、提名和治理委员会、薪酬委员会、财务委员会和技术委员会任职，这些公司包括上市的工程和制造公司The Eastern Company，NFi Group Inc.，一家上市的跨国b制造商，于2025年1月至2025年4月；丨艾伯森公司，Inc.，一家上市的食品和药品零售公司，于2021年4月至2024年10月；Blue Bird Corporation，一家上市的学校BE和特种车辆制造商，于2015年2月至2023年4月；Autob，Inc.，上市的汽车工业数字营销公司，2019年1月至2022年5月；以及上市的化妆品和美容公司雅芳产品有限公司,2016年3月至2020年1月。Galbato先生拥有纽约州立大学经济学学士学位和芝加哥大学工商管理硕士学位。
- Chan W. Galbato has been Senior Advisor to Barington Capital Group, LP, a private investment firm, since March 2025, and Alvarez Marsal Holdings, LLC, a consulting firm, since Augt 2025. Previoly, he was the Chief Executive Officer of Cerber Operations and Advisory Company, LLC, the global operating platform of Cerber Capital Management, a private investment company, from 2012 to 2024. Prior to joining Cerber in 2009, Mr. Galbato served as President and Chief Executive Officer of the Controls Group of Invesys plc, a global technology company. Prior to that, he served as President of Services and of the commercial distribution arm of companies for The Home Depot; President and Chief Executive Officer of Armstrong Floor Products, a division of Armstrong World Indtries; Chief Executive Officer of Choice Parts, a joint venture start up; and President and Chief Executive Officer of Coregis Insurance Company, a GE Capital company. He spent fteen years with General Electric Company, holding several operating and finance leadership positions within their vario indtrial divisions (including Transportation Systems, Aircraft Engines, Medical Systems and Appliances). Mr. Galbato has served on the boards of directors, audit committees, nominating and governance committees, compensation committees, finance committees and technology committees of vario companies, including The Eastern Company, a publicly traded engineering and manufacturing company, since May 2025, NFI Group Inc., a publicly traded multinational b manufacturer, from January 2025 to April 2025; Albertsons Companies, Inc., a publicly traded food and drug retail company, from April 2021 to October 2024; Blue Bird Corporation, a publicly traded manufacturer of school bes and specialty vehicles, from February 2015 to April 2023; Autob, Inc., a publicly traded digital marketing company for the automotive indtry, from January 2019 to May 2022; and Avon Products, Inc., a publicly traded cosmetics and beauty company, from March 2016 to January 2020. Mr. Galbato holds a B.A. in Economics from the State University of New York and an M.B.A. from the University of Chicago.
- Stephen La Neve
-
Stephen La Neve，最近于2019年至2024年担任Globus医疗公司创伤和关节重建业务部门总裁，此前担任肌肉骨骼设备解决方案提供商Globus医疗日本K.K.。2015年至2019年，La Neve先生担任Bone Biologics Corporation的首席执行官，该公司是一家专注于骨再生的医疗器械公司。他还担任Bone Biologics Corporation董事会成员至2022年12月。在此之前，La Neve先生曾于2014年至2015年担任Life Science Enterprises，Inc.的首席执行官，该公司是一家从ETEX Corporation分拆出来的早期生物材料公司，并于2014年担任先进生物材料公司ETEX Corporation的首席执行官，直到Zimmer Holdings，Inc.于2014年底收购ETEX Holdings，Inc.的业务。在担任该职务之前，La Neve先生是SkelRegen，LLC的首席执行官和董事会成员、Becton Dickinson Preanalytical Systems的全球总裁、美敦力 Spine and Biologics，Inc.的全球总裁，以及美敦力日本公司的总裁。在他职业生涯的早期，La Neve先生曾在国内和国际上担任过三家诊断公司的各种商业职务：Becton Dickinson、罗氏和EM诊断系统。他曾在医疗器械和诊断领域的多家医疗保健公司担任董事会成员，目前包括Insight Medbotics，一家为介入肿瘤学开发MRI引导机器人技术的公司。La Neve先生拥有宾夕法尼亚州立大学的健康规划和管理学士学位和西切斯特大学的MBA学位。他是Omicron Delta Epsilon的成员，这是一个表彰学术卓越和经济学成就的国际荣誉协会。
Stephen La Neve,served as President of the Trauma and Joint Reconstruction business unit of Globus Medical Inc. and President of Globus Medical Japan K.K. (NYSE: GMED), Chief Executive Officer and Board Member of Bone Biologics Corporation (NASDAQ: BBLG), Global President of Becton Dickinson Preanalytical Systems (NYSE: BDX), and as Global Sector President for Medtronic's Spine and Biologics Division (NYSE: MDT). - Stephen La Neve，最近于2019年至2024年担任Globus医疗公司创伤和关节重建业务部门总裁，此前担任肌肉骨骼设备解决方案提供商Globus医疗日本K.K.。2015年至2019年，La Neve先生担任Bone Biologics Corporation的首席执行官，该公司是一家专注于骨再生的医疗器械公司。他还担任Bone Biologics Corporation董事会成员至2022年12月。在此之前，La Neve先生曾于2014年至2015年担任Life Science Enterprises，Inc.的首席执行官，该公司是一家从ETEX Corporation分拆出来的早期生物材料公司，并于2014年担任先进生物材料公司ETEX Corporation的首席执行官，直到Zimmer Holdings，Inc.于2014年底收购ETEX Holdings，Inc.的业务。在担任该职务之前，La Neve先生是SkelRegen，LLC的首席执行官和董事会成员、Becton Dickinson Preanalytical Systems的全球总裁、美敦力 Spine and Biologics，Inc.的全球总裁，以及美敦力日本公司的总裁。在他职业生涯的早期，La Neve先生曾在国内和国际上担任过三家诊断公司的各种商业职务：Becton Dickinson、罗氏和EM诊断系统。他曾在医疗器械和诊断领域的多家医疗保健公司担任董事会成员，目前包括Insight Medbotics，一家为介入肿瘤学开发MRI引导机器人技术的公司。La Neve先生拥有宾夕法尼亚州立大学的健康规划和管理学士学位和西切斯特大学的MBA学位。他是Omicron Delta Epsilon的成员，这是一个表彰学术卓越和经济学成就的国际荣誉协会。
- Stephen La Neve,served as President of the Trauma and Joint Reconstruction business unit of Globus Medical Inc. and President of Globus Medical Japan K.K. (NYSE: GMED), Chief Executive Officer and Board Member of Bone Biologics Corporation (NASDAQ: BBLG), Global President of Becton Dickinson Preanalytical Systems (NYSE: BDX), and as Global Sector President for Medtronic's Spine and Biologics Division (NYSE: MDT).
- Steven F. Mayer
-
Steven F. Mayer自2002年11月起担任Cerberus Capital Management，L.P.和/或Cerberus California，LLC及其前身实体的高级董事总经理或董事总经理，还担任Cerberus全球私募股权部门的联席主管。在2002年加入Cerberus之前，自2001年起，Mayer先生担任Gores Technology集团执行董事总经理。在加入Gores之前，从1996年到2001年，Mayer先生担任Libra Capital Partners，L.P.的董事总经理。从1994年到1996年，Mayer先生担任Aries Capital Group，LLC的董事总经理，该公司是他与他人共同创立的一家私募股权投资公司。从1992年到1994年，Mayer先生是Apollo Advisors，L.P.和Lion Advisors，L.P.附属私人投资公司的负责人。在此之前，Mayer先生是Sullivan & Cromwell的一名律师。Mayer先生是Avon Products, Inc. NYSE：AVP、GRIFOLS, S.A.（NASDAQ：GRFS）、New Avon，LLC、Spyglass Entertainment Holdings，LLC、Staples Solutions，B.V。、Starrus Holdings Limited和YP Holdings，LLC的董事会成员。Mayer先生以优异成绩获得普林斯顿大学的学士学位，并以优异成绩获得哈佛法学院的法学博士学位。
Steven F. Mayer has served as Chairman of the Operations Advisory Counsel and Senior Advisor to the private credit group of TCW, a $200 billion investment group, since 2023; a senior strategic advisor to Red Arts Capital, a private equity firm foced on supply chain investments, since 2024; Chairman and Co founder of 9Squared, LLC, a technology company, since 2023; and Chief Executive Officer of Dedication Capital, LLC, a privately held investment vehicle, since 2018. Previoly, Mr. Mayer was the Executive Chairman of Grifols, SA, a publicly traded global healthcare company, from 2022 to 2023 and Senior Managing Director, Co Head of Global Private Equity, and Chairman of the Investment Committee of Cerber Capital Management, L.P. from 2002 to 2018. Mr. Mayer currently serves on the Board of Directors of Pace Indtries Holdings, LLC, a privately held die cast manufacturer in North America; the holding company of Landmark Structures I, LP, a privately held engineering and contracting company in North America; and 9Squared LLC, an early stage, privately held technology company, and previoly served on the Boards of Directors of Grifols, SA, a global healthcare company, from June 2011 to February 2023 and Knowles Corporation, a manufacturer of specialty electronic components, from May 2019 through October 2019. Mr. Mayer holds a J.D. from Harvard Law School and a B.A. in public and international affairs from Princeton University. Mr. Mayer was appointed to Board in connection with the Company's debt refinancing in June 2025 pursuant to the terms of the Governance Agreement dated June 6, 2025, by and beten the Company and TCW Asset Management Company LLC. - Steven F. Mayer自2002年11月起担任Cerberus Capital Management，L.P.和/或Cerberus California，LLC及其前身实体的高级董事总经理或董事总经理，还担任Cerberus全球私募股权部门的联席主管。在2002年加入Cerberus之前，自2001年起，Mayer先生担任Gores Technology集团执行董事总经理。在加入Gores之前，从1996年到2001年，Mayer先生担任Libra Capital Partners，L.P.的董事总经理。从1994年到1996年，Mayer先生担任Aries Capital Group，LLC的董事总经理，该公司是他与他人共同创立的一家私募股权投资公司。从1992年到1994年，Mayer先生是Apollo Advisors，L.P.和Lion Advisors，L.P.附属私人投资公司的负责人。在此之前，Mayer先生是Sullivan & Cromwell的一名律师。Mayer先生是Avon Products, Inc. NYSE：AVP、GRIFOLS, S.A.（NASDAQ：GRFS）、New Avon，LLC、Spyglass Entertainment Holdings，LLC、Staples Solutions，B.V。、Starrus Holdings Limited和YP Holdings，LLC的董事会成员。Mayer先生以优异成绩获得普林斯顿大学的学士学位，并以优异成绩获得哈佛法学院的法学博士学位。
- Steven F. Mayer has served as Chairman of the Operations Advisory Counsel and Senior Advisor to the private credit group of TCW, a $200 billion investment group, since 2023; a senior strategic advisor to Red Arts Capital, a private equity firm foced on supply chain investments, since 2024; Chairman and Co founder of 9Squared, LLC, a technology company, since 2023; and Chief Executive Officer of Dedication Capital, LLC, a privately held investment vehicle, since 2018. Previoly, Mr. Mayer was the Executive Chairman of Grifols, SA, a publicly traded global healthcare company, from 2022 to 2023 and Senior Managing Director, Co Head of Global Private Equity, and Chairman of the Investment Committee of Cerber Capital Management, L.P. from 2002 to 2018. Mr. Mayer currently serves on the Board of Directors of Pace Indtries Holdings, LLC, a privately held die cast manufacturer in North America; the holding company of Landmark Structures I, LP, a privately held engineering and contracting company in North America; and 9Squared LLC, an early stage, privately held technology company, and previoly served on the Boards of Directors of Grifols, SA, a global healthcare company, from June 2011 to February 2023 and Knowles Corporation, a manufacturer of specialty electronic components, from May 2019 through October 2019. Mr. Mayer holds a J.D. from Harvard Law School and a B.A. in public and international affairs from Princeton University. Mr. Mayer was appointed to Board in connection with the Company's debt refinancing in June 2025 pursuant to the terms of the Governance Agreement dated June 6, 2025, by and beten the Company and TCW Asset Management Company LLC.
- Joseph E. Whitters
-
Joseph E. Whitters，自2018年7月起担任Accuray Incorporated董事会成员。自2005年以来，惠特斯一直担任私募股权公司Frazier Healthcare的顾问/顾问。从1986年到2005年，Whitters先生在First Health Group Corp.（一家上市的管理式医疗公司）担任各种职务，最近担任其首席财务官。此前，他还曾在1984年至1986年期间担任公开上市的医疗保健管理公司United Healthcare Corp的财务总监。在此之前，Whitters先生曾担任上市卡车运输公司Overland Express的会计和税务经理，他的公共会计职业生涯始于Peat Marwick（现毕马威）。Whitters曾在多家上市公司的董事会和审计委员会任职，其中包括全球美容设备公司Cutera, Inc.，从2019年2月至2023年6月，InfuSystem Holdings，Inc.，一家输液泵及相关产品和服务的公开交易供应商，从2012年4月至2019年5月；医疗保健和安全技术解决方案私营公司，从2017年10月至2018年6月；PRGX全球，Inc.，一家恢复审计和支出分析服务的私营供应商，从2013年2月至2021年3月；SPARK网络，一家优质在线约会网站和移动应用程序的私营运营商，2021年7月至2024年2月；以及私营空中医疗运输和空中旅游公司Air Methods公司，2016年3月至2017年4月。Whitters还曾是多家私营公司的顾问或董事会成员。Whitters先生拥有路德学院会计学学士学位。
Joseph E. Whitters has served as a member of Board since July 2018. Mr. Whitters has been an advisor/consultant to Frazier Healthcare, a private equity firm, since 2005. From 1986 to 2005, Mr. Whitters served in vario capacities with First Health Group Corp., a publicly traded managed care company, most recently as its Chief Financial Officer. He also previoly served as the Controller for United Healthcare Corp, a publicly traded health care management company, from 1984 to 1986. Prior to that, Mr. Whitters served as the Manager of Accounting and Taxation for Overland Express, a publicly traded trucking company, and he began his career in public accounting with Peat Marwick (now KPMG). Whitters has served on the boards of directors and audit committees of vario public companies, including Cutera, Inc., a global aesthetics device company, from February 2019 through June 2023; Infystem Holdings, Inc., a publicly traded provider of infion pumps and related products and services, from April 2012 through May 2019; Analogic Corporation, a private healthcare and security technology solutions company, from October 2017 through June 2018; PRGX Global, Inc., a private provider of recovery audit and spend analytics services, from February 2013 to March 2021; Spark Networks, a private operator of premium online dating sites and mobile applications, from July 2021 to February 2024; and Air Methods Corp., a private air medical transportation and air tism company, from March 2016 through April 2017. Mr. Whitters has also been an advisor or board member of several private companies. Mr. Whitters holds a B.A. in Accounting from Luther College. - Joseph E. Whitters，自2018年7月起担任Accuray Incorporated董事会成员。自2005年以来，惠特斯一直担任私募股权公司Frazier Healthcare的顾问/顾问。从1986年到2005年，Whitters先生在First Health Group Corp.（一家上市的管理式医疗公司）担任各种职务，最近担任其首席财务官。此前，他还曾在1984年至1986年期间担任公开上市的医疗保健管理公司United Healthcare Corp的财务总监。在此之前，Whitters先生曾担任上市卡车运输公司Overland Express的会计和税务经理，他的公共会计职业生涯始于Peat Marwick（现毕马威）。Whitters曾在多家上市公司的董事会和审计委员会任职，其中包括全球美容设备公司Cutera, Inc.，从2019年2月至2023年6月，InfuSystem Holdings，Inc.，一家输液泵及相关产品和服务的公开交易供应商，从2012年4月至2019年5月；医疗保健和安全技术解决方案私营公司，从2017年10月至2018年6月；PRGX全球，Inc.，一家恢复审计和支出分析服务的私营供应商，从2013年2月至2021年3月；SPARK网络，一家优质在线约会网站和移动应用程序的私营运营商，2021年7月至2024年2月；以及私营空中医疗运输和空中旅游公司Air Methods公司，2016年3月至2017年4月。Whitters还曾是多家私营公司的顾问或董事会成员。Whitters先生拥有路德学院会计学学士学位。
- Joseph E. Whitters has served as a member of Board since July 2018. Mr. Whitters has been an advisor/consultant to Frazier Healthcare, a private equity firm, since 2005. From 1986 to 2005, Mr. Whitters served in vario capacities with First Health Group Corp., a publicly traded managed care company, most recently as its Chief Financial Officer. He also previoly served as the Controller for United Healthcare Corp, a publicly traded health care management company, from 1984 to 1986. Prior to that, Mr. Whitters served as the Manager of Accounting and Taxation for Overland Express, a publicly traded trucking company, and he began his career in public accounting with Peat Marwick (now KPMG). Whitters has served on the boards of directors and audit committees of vario public companies, including Cutera, Inc., a global aesthetics device company, from February 2019 through June 2023; Infystem Holdings, Inc., a publicly traded provider of infion pumps and related products and services, from April 2012 through May 2019; Analogic Corporation, a private healthcare and security technology solutions company, from October 2017 through June 2018; PRGX Global, Inc., a private provider of recovery audit and spend analytics services, from February 2013 to March 2021; Spark Networks, a private operator of premium online dating sites and mobile applications, from July 2021 to February 2024; and Air Methods Corp., a private air medical transportation and air tism company, from March 2016 through April 2017. Mr. Whitters has also been an advisor or board member of several private companies. Mr. Whitters holds a B.A. in Accounting from Luther College.
高管简历
中英对照 | 中文 | 英文- Jesse Chew
Jesse Chew自2018年10月起担任我们的高级副总裁，总法律顾问兼公司秘书。此前，周先生曾于2018年7月至2018年10月担任我们的Vice President，副总法律顾问以及我们的临时总法律顾问兼公司秘书，2017年7月至2018年7月担任高级公司法律顾问，2014年1月至2017年6月担任公司法律顾问。在加入公司之前，Chew先生是Wilson Sonsini Goodrich and Rosati，P.C.律师事务所的合伙人。Chew先生拥有加州大学戴维斯分校（University of California，Davis）的英语和政治学学士学位以及南加州大学（University of Southern California）的法学博士学位。
Jesse Chew has served as Senior Vice President, Chief Legal Officer and Corporate Secretary since April 2023 and Senior Vice President, General Counsel and Corporate Secretary from October 2018 to March 2023. Previoly, Mr. Chew served as Vice President, Associate General Counsel as ll as Interim General Counsel and Corporate Secretary from July 2018 to October 2018, Senior Corporate Counsel from July 2017 to July 2018 and Corporate Counsel from January 2014 to June 2017. Prior to joining the Company, Mr. Chew was an associate at the law firm Wilson Sonsini Goodrich and Rosati, P.C. Mr. Chew holds a B.A. in English and Political Science from the University of California, Davis and a J.D. from the University of Southern California.- Jesse Chew自2018年10月起担任我们的高级副总裁，总法律顾问兼公司秘书。此前，周先生曾于2018年7月至2018年10月担任我们的Vice President，副总法律顾问以及我们的临时总法律顾问兼公司秘书，2017年7月至2018年7月担任高级公司法律顾问，2014年1月至2017年6月担任公司法律顾问。在加入公司之前，Chew先生是Wilson Sonsini Goodrich and Rosati，P.C.律师事务所的合伙人。Chew先生拥有加州大学戴维斯分校（University of California，Davis）的英语和政治学学士学位以及南加州大学（University of Southern California）的法学博士学位。
- Jesse Chew has served as Senior Vice President, Chief Legal Officer and Corporate Secretary since April 2023 and Senior Vice President, General Counsel and Corporate Secretary from October 2018 to March 2023. Previoly, Mr. Chew served as Vice President, Associate General Counsel as ll as Interim General Counsel and Corporate Secretary from July 2018 to October 2018, Senior Corporate Counsel from July 2017 to July 2018 and Corporate Counsel from January 2014 to June 2017. Prior to joining the Company, Mr. Chew was an associate at the law firm Wilson Sonsini Goodrich and Rosati, P.C. Mr. Chew holds a B.A. in English and Political Science from the University of California, Davis and a J.D. from the University of Southern California.
- Ali Pervaiz
Ali Pervaiz，自2022年5月起担任Accuray Incorporated高级副总裁兼首席财务官。此前，Pervaiz先生于2020年8月至2022年5月担任Accuray Incorporated全球商业运营副总裁。在加入本公司之前，Pervaiz先生曾在通用电气公司的子公司、全球医疗技术、药物诊断和数字解决方案创新者GE Healthcare任职超过15年，担任高级财务和运营领导职务，最近的职务是在2018年9月至2020年1月期间担任执行-利润率增长PMO Leader，专注于全球影像业务的利润率扩张，在2017年1月至2018年9月期间担任执行-前进Leader，专注于商业战略和财务转型。在GE Healthcare任职期间，Pervaiz先生曾被选入公司审计人员项目并毕业，他还曾在GE Healthcare担任美国商业诊断成像设备和美国商业生命支持解决方案业务部门的首席财务官。Pervaiz先生拥有芝加哥大学布斯商学院的工商管理硕士学位，专注于金融和运营，威斯康星医学院的医疗保健技术管理硕士学位和马凯特大学的学士学位。
Ali Pervaiz has served as Senior Vice President, Chief Financial Officer since May 2022. Previoly, Mr. Pervaiz served as Vice President, Global Commercial Operations from Augt 2020 through May 2022. Prior to joining the Company, Mr. Pervaiz was with GE Healthcare, a global medical technology, pharmaceutical diagnostics, and digital solutions innovator and subsidiary of General Electric Company, for over 15 years in senior financial and operating leadership roles, most recently as Executive – Margin Growth PMO Leader foced on Margin Expansion for the Global Imaging biness from September 2018 to January 2020 and Executive – Advance Leader foced on Commercial Strategy & Finance Transformation from January 2017 to September 2018. During his tenure at GE Healthcare, Mr. Pervaiz, who was selected for and graduated from the Corporate Audit Staff program, also previoly held biness unit Chief Financial Officer roles at GE Healthcare for the Commercial Diagnostic Imaging Equipment and Commercial Life Support Solutions binesses. Mr. Pervaiz holds an M.B.A. from the University of Chicago Booth School of Biness with foc on finance and operations, an M.S. in healthcare technologies management from the Medical College of Wisconsin and a B.S. from Marquette University.- Ali Pervaiz，自2022年5月起担任Accuray Incorporated高级副总裁兼首席财务官。此前，Pervaiz先生于2020年8月至2022年5月担任Accuray Incorporated全球商业运营副总裁。在加入本公司之前，Pervaiz先生曾在通用电气公司的子公司、全球医疗技术、药物诊断和数字解决方案创新者GE Healthcare任职超过15年，担任高级财务和运营领导职务，最近的职务是在2018年9月至2020年1月期间担任执行-利润率增长PMO Leader，专注于全球影像业务的利润率扩张，在2017年1月至2018年9月期间担任执行-前进Leader，专注于商业战略和财务转型。在GE Healthcare任职期间，Pervaiz先生曾被选入公司审计人员项目并毕业，他还曾在GE Healthcare担任美国商业诊断成像设备和美国商业生命支持解决方案业务部门的首席财务官。Pervaiz先生拥有芝加哥大学布斯商学院的工商管理硕士学位，专注于金融和运营，威斯康星医学院的医疗保健技术管理硕士学位和马凯特大学的学士学位。
- Ali Pervaiz has served as Senior Vice President, Chief Financial Officer since May 2022. Previoly, Mr. Pervaiz served as Vice President, Global Commercial Operations from Augt 2020 through May 2022. Prior to joining the Company, Mr. Pervaiz was with GE Healthcare, a global medical technology, pharmaceutical diagnostics, and digital solutions innovator and subsidiary of General Electric Company, for over 15 years in senior financial and operating leadership roles, most recently as Executive – Margin Growth PMO Leader foced on Margin Expansion for the Global Imaging biness from September 2018 to January 2020 and Executive – Advance Leader foced on Commercial Strategy & Finance Transformation from January 2017 to September 2018. During his tenure at GE Healthcare, Mr. Pervaiz, who was selected for and graduated from the Corporate Audit Staff program, also previoly held biness unit Chief Financial Officer roles at GE Healthcare for the Commercial Diagnostic Imaging Equipment and Commercial Life Support Solutions binesses. Mr. Pervaiz holds an M.B.A. from the University of Chicago Booth School of Biness with foc on finance and operations, an M.S. in healthcare technologies management from the Medical College of Wisconsin and a B.S. from Marquette University.
- Sandeep Chalke
Sandeep Chalke，自2022年5月起担任Accuray Incorporated高级副总裁兼首席商务官。在加入本公司之前，Chalke先生于2020年4月至2022年5月在全球呼吸护理私营制造商Vyaire Medical，Inc.担任亚太和拉丁美洲地区总裁。在此之前，他于2017年2月至2019年7月担任医疗器械公司美敦力的亚洲太平洋地区糖尿病集团副总裁。2015年5月至2017年1月，查尔克在私营医疗设备公司Acelity L.P担任高级伤口敷料副总裁。查尔克的职业生涯始于通用电气公司，这是一家高科技工业上市公司，曾担任多个领导职位，包括通用电气医疗集团。查尔克先生拥有莱斯特大学的工商管理硕士学位和孟买大学的医疗电子学学位。
Sandeep Chalke has served as Senior Vice President, Chief Commercial Officer since May 2022. He also served as Interim CEO of the Company from September 3, 2024 through October 15, 2024 while Ms. Winter took a medical leave of absence from the Company. Prior to joining the Company, Mr. Chalke served as President, Asia Pacific and Latin America regions at Vyaire Medical, Inc., a private global respiratory care manufacturer, from April 2020 to May 2022. Prior to that, he was Vice President of the Diabetes Group in Asian Pacific for Medtronic plc, a medical device company, from February 2017 to July 2019. From May 2015 to January 2017, Mr. Chalke served as Vice President, Advanced Wound Dressing at Acelity L.P, a private medical device company. Mr. Chalke started his career at General Electric Company, a public high tech indtrial company, where he served in many leadership positions, including at GE Healthcare. Mr. Chalke holds an M.B.A. from the University of Leicester and a Medical Electronics degree from the University of Mumbai.- Sandeep Chalke，自2022年5月起担任Accuray Incorporated高级副总裁兼首席商务官。在加入本公司之前，Chalke先生于2020年4月至2022年5月在全球呼吸护理私营制造商Vyaire Medical，Inc.担任亚太和拉丁美洲地区总裁。在此之前，他于2017年2月至2019年7月担任医疗器械公司美敦力的亚洲太平洋地区糖尿病集团副总裁。2015年5月至2017年1月，查尔克在私营医疗设备公司Acelity L.P担任高级伤口敷料副总裁。查尔克的职业生涯始于通用电气公司，这是一家高科技工业上市公司，曾担任多个领导职位，包括通用电气医疗集团。查尔克先生拥有莱斯特大学的工商管理硕士学位和孟买大学的医疗电子学学位。
- Sandeep Chalke has served as Senior Vice President, Chief Commercial Officer since May 2022. He also served as Interim CEO of the Company from September 3, 2024 through October 15, 2024 while Ms. Winter took a medical leave of absence from the Company. Prior to joining the Company, Mr. Chalke served as President, Asia Pacific and Latin America regions at Vyaire Medical, Inc., a private global respiratory care manufacturer, from April 2020 to May 2022. Prior to that, he was Vice President of the Diabetes Group in Asian Pacific for Medtronic plc, a medical device company, from February 2017 to July 2019. From May 2015 to January 2017, Mr. Chalke served as Vice President, Advanced Wound Dressing at Acelity L.P, a private medical device company. Mr. Chalke started his career at General Electric Company, a public high tech indtrial company, where he served in many leadership positions, including at GE Healthcare. Mr. Chalke holds an M.B.A. from the University of Leicester and a Medical Electronics degree from the University of Mumbai.
- Leonel Peralta
Leonel Peralta，曾于2021年9月至2025年1月在医疗技术制造商Siemens Healthineers担任副总裁兼超声部门全球运营主管。在此之前，他于2015年2月至2021年9月在全球医疗保健技术公司美敦力 PLC担任糖尿病全球运营副总裁。在加入美敦力之前，Peralta先生还曾在Hill-Rom（Baxter）、KCI Medical（3M）和GE Healthcare担任多个管理职位。Peralta先生获得了芝加哥大学的工商管理硕士学位、迈阿密大学的机械工程、工程和管理硕士学位，以及佛罗里达国际大学的机械工程学士学位。
Leonel Peralta has served as Senior Vice President, Chief Operations Officer since February 2025. Previoly, Mr. Peralta served as Vice President, Head of Global Operations for the ultrasound division at Siemens Healthineers, a medical technology manufacturer, from September 2021 to January 2025. Prior to that, he served as VP, Global Operations, Diabetes at Medtronic plc, a global healthcare technology company, from February 2015 to September 2021. Prior to joining Medtronic, Mr. Peralta also served in vario management positions at Hill Rom (Baxter), KCI Medical (3M), and GE Healthcare. Mr. Peralta received an M.B.A. from the University of Chicago, an M.S. in Mechanical Engineering, Engineering and Management from the University of Miami, and a B.S. in Mechanical Engineering from Florida International University.- Leonel Peralta，曾于2021年9月至2025年1月在医疗技术制造商Siemens Healthineers担任副总裁兼超声部门全球运营主管。在此之前，他于2015年2月至2021年9月在全球医疗保健技术公司美敦力 PLC担任糖尿病全球运营副总裁。在加入美敦力之前，Peralta先生还曾在Hill-Rom（Baxter）、KCI Medical（3M）和GE Healthcare担任多个管理职位。Peralta先生获得了芝加哥大学的工商管理硕士学位、迈阿密大学的机械工程、工程和管理硕士学位，以及佛罗里达国际大学的机械工程学士学位。
- Leonel Peralta has served as Senior Vice President, Chief Operations Officer since February 2025. Previoly, Mr. Peralta served as Vice President, Head of Global Operations for the ultrasound division at Siemens Healthineers, a medical technology manufacturer, from September 2021 to January 2025. Prior to that, he served as VP, Global Operations, Diabetes at Medtronic plc, a global healthcare technology company, from February 2015 to September 2021. Prior to joining Medtronic, Mr. Peralta also served in vario management positions at Hill Rom (Baxter), KCI Medical (3M), and GE Healthcare. Mr. Peralta received an M.B.A. from the University of Chicago, an M.S. in Mechanical Engineering, Engineering and Management from the University of Miami, and a B.S. in Mechanical Engineering from Florida International University.
- Stephen La Neve
Stephen La Neve，最近于2019年至2024年担任Globus医疗公司创伤和关节重建业务部门总裁，此前担任肌肉骨骼设备解决方案提供商Globus医疗日本K.K.。2015年至2019年，La Neve先生担任Bone Biologics Corporation的首席执行官，该公司是一家专注于骨再生的医疗器械公司。他还担任Bone Biologics Corporation董事会成员至2022年12月。在此之前，La Neve先生曾于2014年至2015年担任Life Science Enterprises，Inc.的首席执行官，该公司是一家从ETEX Corporation分拆出来的早期生物材料公司，并于2014年担任先进生物材料公司ETEX Corporation的首席执行官，直到Zimmer Holdings，Inc.于2014年底收购ETEX Holdings，Inc.的业务。在担任该职务之前，La Neve先生是SkelRegen，LLC的首席执行官和董事会成员、Becton Dickinson Preanalytical Systems的全球总裁、美敦力 Spine and Biologics，Inc.的全球总裁，以及美敦力日本公司的总裁。在他职业生涯的早期，La Neve先生曾在国内和国际上担任过三家诊断公司的各种商业职务：Becton Dickinson、罗氏和EM诊断系统。他曾在医疗器械和诊断领域的多家医疗保健公司担任董事会成员，目前包括Insight Medbotics，一家为介入肿瘤学开发MRI引导机器人技术的公司。La Neve先生拥有宾夕法尼亚州立大学的健康规划和管理学士学位和西切斯特大学的MBA学位。他是Omicron Delta Epsilon的成员，这是一个表彰学术卓越和经济学成就的国际荣誉协会。
Stephen La Neve,served as President of the Trauma and Joint Reconstruction business unit of Globus Medical Inc. and President of Globus Medical Japan K.K. (NYSE: GMED), Chief Executive Officer and Board Member of Bone Biologics Corporation (NASDAQ: BBLG), Global President of Becton Dickinson Preanalytical Systems (NYSE: BDX), and as Global Sector President for Medtronic's Spine and Biologics Division (NYSE: MDT).- Stephen La Neve，最近于2019年至2024年担任Globus医疗公司创伤和关节重建业务部门总裁，此前担任肌肉骨骼设备解决方案提供商Globus医疗日本K.K.。2015年至2019年，La Neve先生担任Bone Biologics Corporation的首席执行官，该公司是一家专注于骨再生的医疗器械公司。他还担任Bone Biologics Corporation董事会成员至2022年12月。在此之前，La Neve先生曾于2014年至2015年担任Life Science Enterprises，Inc.的首席执行官，该公司是一家从ETEX Corporation分拆出来的早期生物材料公司，并于2014年担任先进生物材料公司ETEX Corporation的首席执行官，直到Zimmer Holdings，Inc.于2014年底收购ETEX Holdings，Inc.的业务。在担任该职务之前，La Neve先生是SkelRegen，LLC的首席执行官和董事会成员、Becton Dickinson Preanalytical Systems的全球总裁、美敦力 Spine and Biologics，Inc.的全球总裁，以及美敦力日本公司的总裁。在他职业生涯的早期，La Neve先生曾在国内和国际上担任过三家诊断公司的各种商业职务：Becton Dickinson、罗氏和EM诊断系统。他曾在医疗器械和诊断领域的多家医疗保健公司担任董事会成员，目前包括Insight Medbotics，一家为介入肿瘤学开发MRI引导机器人技术的公司。La Neve先生拥有宾夕法尼亚州立大学的健康规划和管理学士学位和西切斯特大学的MBA学位。他是Omicron Delta Epsilon的成员，这是一个表彰学术卓越和经济学成就的国际荣誉协会。
- Stephen La Neve,served as President of the Trauma and Joint Reconstruction business unit of Globus Medical Inc. and President of Globus Medical Japan K.K. (NYSE: GMED), Chief Executive Officer and Board Member of Bone Biologics Corporation (NASDAQ: BBLG), Global President of Becton Dickinson Preanalytical Systems (NYSE: BDX), and as Global Sector President for Medtronic's Spine and Biologics Division (NYSE: MDT).